• Mangoceuticals’ former wholly owned unit MangoRx IP Holdings secured USD 2.5 million from two strategic investors at the subsidiary level.
• Initial USD 1.75 million tranche closed for a 17.5% post-acquisition membership interest; investment does not issue MGRX common stock.
• Second tranche totals USD 750,000 for the remaining 7.5% interest, due within 60 days or by Nov. 28, 2026.
• Investors will hold 25% of MangoRx IP; proceeds target commercialization of the MGX-0024 antiviral patent portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011550PRIMZONEFULLFEED9838145) on October 01, 2026, and is solely responsible for the information contained therein.